Karyopharm executive cash retention program disclosure triggers KPTI plunge
- July 17 8-K revealed 2026 Leadership Cash Retention Program approved July 13 for key execs ahead of catalysts
- Awards: $1.725M to CEO Richard Paulson, $725k to CMO, $625-640k to CDO and CFO; replaces prior bonus guarantees
- Filing states purpose is retention during 'several meaningful catalysts' including mid-2026 Phase 3 endometrial cancer data
- Investors viewed large cash payouts negatively, signaling retention risks or uncertainty before binary trial readout
- Stock closed $9.51 (up 1.4%) July 17 then fell ~21% AH to $7.50; extended losses to ~28% intraday July 20
- Heightened sensitivity follows March 2026 SENTRY trial missing one co-primary endpoint; upcoming XPORT-EC-042 data seen as high-stakes
- No other specific news on July 20; retail chatter on X questioned the announcement and expressed bearishness
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.